Clinicopathological and Prognostic Significance of SMAD4 in Non-small Cell Lung Cancer: A Meta-analysis and Database Validation

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2023 Jul 21

PMID 37478236

Authors

Zhiqiang Li

Yunfei Huang

Rongsheng Zhou

Zhicheng Li

Qitao Yan

Affiliations

Soon will be listed here.

Abstract

Background: The relationship between SMAD family member 4 (SMAD4) and the clinicopathological and prognostic significance of non-small cell lung cancer (NSCLC) patients is unclear. Our aim was to investigate the association between SMAD4 expression and clinicopathological parameters and NSCLC prognosis.

Methods: We searched articles in databases from inception to July 2022 to retrieve literature related to SMAD4 expression and the clinicopathological and/or prognostic significance of NSCLC patients. Odds ratios (ORs), hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. We evaluated the expression of SMAD4 and overall survival (OS) in NSCLC using the Kaplan-Meier plotter database.

Results: Eight articles with 1461 NSCLC patients were included. SMAD4 expression was related to tumor differentiation (OR = 0.359, 95% CI: 0.238-0.543, P = .000), lymph node metastasis (OR = 0.469, 95% CI: 0.04-0.725, P = .001), tumor node metastasis stage (OR = 0.238, 95% CI: 0.156-0.362, P = .000) and good OS (HR = 0.592, 95% CI: 0.332-0.853, P = .000) in NSCLC. There was no significant association between SMAD4 expression and age (OR = 0.822, 95% CI: 0.515-1.312, P = .411) or sex (OR = 1.056, 95% CI: 0.675-1.653, P = .811). Furthermore, SMAD4 expression was lower in NSCLC, and a good prognosis in NSCLC (HR = 0.6, 95% CI = 0.51-0.72, P = 4.2 e-9) was shown to correlate with higher SMAD4 expression using the Kaplan-Meier Plotter database.

Conclusion: SMAD4 expression is lower in NSCLC and correlated with lymph node metastasis, tumor differentiation, tumor node metastasis stage and good OS for NSCLC patients.

Citing Articles

Enhancing radiotherapy in triple-negative breast cancer with hesperetin-induced ferroptosis via AURKA targeting nanocomposites.

Guo Y, Wang H, Wang X, Chen K, Feng L J Nanobiotechnology. 2024; 22(1):744.

PMID: 39614277 PMC: 11607925. DOI: 10.1186/s12951-024-02987-3.

References

Liu J, Ren G, Li K, Liu Z, Wang Y, Chen T . The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma. Cell Death Differ. 2021; 29(4):818-831. PMC: 8990017. DOI: 10.1038/s41418-021-00897-7. View

Tong X, Liu H, Zhao H, Xu S, Li Y, Han L . [The role of Smad4 and MAPK proteins in signal transduction pathway in non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2007; 28(10):741-5. View

Javle M, Li Y, Tan D, Dong X, Chang P, Kar S . Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014; 9(1):e85942. PMC: 3896410. DOI: 10.1371/journal.pone.0085942. View

Ding Z, Wu C, Chu G, Xiao Y, Ho D, Zhang J . SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011; 470(7333):269-73. PMC: 3753179. DOI: 10.1038/nature09677. View

Wang Y, Xue Q, Zheng Q, Jin Y, Shen X, Yang M . SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer. Lab Invest. 2020; 101(4):463-476. DOI: 10.1038/s41374-020-00517-x. View

Yuan T, Chen Z, Yan F, Qian M, Luo H, Ye S . Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein. Mol Oncol. 2019; 14(1):197-210. PMC: 6944132. DOI: 10.1002/1878-0261.12596. View

Liu J, Cho S, Akkanti B, Jin N, Mao J, Long W . ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis. Cell Rep. 2015; 10(9):1599-1613. PMC: 7405934. DOI: 10.1016/j.celrep.2015.02.014. View

Jain D, Nambirajan A, Chen G, Geisinger K, Hiroshima K, Layfield L . NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. J Thorac Oncol. 2022; 17(6):793-805. DOI: 10.1016/j.jtho.2022.02.013. View

Eser P, Janne P . TGFβ pathway inhibition in the treatment of non-small cell lung cancer. Pharmacol Ther. 2017; 184:112-130. DOI: 10.1016/j.pharmthera.2017.11.004. View

10.

Yang Y, Yang N, Jiang J . Exosomal circ_PTPRA inhibits tumorigenesis and promotes radiosensitivity in colorectal cancer by enriching the level of SMAD4 via competitively binding to miR-671-5p. Cytotechnology. 2022; 74(1):51-64. PMC: 8817021. DOI: 10.1007/s10616-021-00506-y. View

11.

Ziemke M, Patil T, Nolan K, Tippimanchai D, Malkoski S . Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer. 2017; 109:28-35. PMC: 5501281. DOI: 10.1016/j.lungcan.2017.04.017. View

12.

Lai X, Li J, Tang L, Chen W, Zhang L, Xiong L . MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer. Int J Mol Sci. 2020; 21(4). PMC: 7072809. DOI: 10.3390/ijms21041193. View

13.

Yaghoubi N, Avval F, Khazaei M, Sahebkar A, Aghaee-Bakhtiari S . High Diagnostic and Prognostic Value of miRNAs Compared with the Carcinoembryonic Antigen As A Traditional Tumor Marker. Anticancer Agents Med Chem. 2021; 22(2):206-214. DOI: 10.2174/1871520621666210608094908. View

14.

Abughanimeh O, Kaur A, El Osta B, Ganti A . Novel targeted therapies for advanced non-small lung cancer. Semin Oncol. 2022; 49(3-4):326-336. DOI: 10.1053/j.seminoncol.2022.03.003. View

15.

Ke Z, Zhang X, Ma L, Wang L . Deleted in pancreatic carcinoma locus 4/Smad4 participates in the regulation of apoptosis by affecting the Bcl-2/Bax balance in non-small cell lung cancer. Hum Pathol. 2008; 39(10):1438-45. DOI: 10.1016/j.humpath.2008.03.006. View

16.

Wilentz R, Su G, Dai J, Sparks A, Argani P, Sohn T . Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol. 2000; 156(1):37-43. PMC: 1868651. DOI: 10.1016/S0002-9440(10)64703-7. View

17.

Loomans H, Andl C . Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion. Cancers (Basel). 2015; 7(1):70-91. PMC: 4381251. DOI: 10.3390/cancers7010070. View

18.

Guo X, Li M, Wang X, Pan Y, Li J . Correlation between loss of Smad4 and clinical parameters of non-small cell lung cancer: an observational cohort study. BMC Pulm Med. 2021; 21(1):111. PMC: 8017835. DOI: 10.1186/s12890-021-01480-z. View

19.

Siegel P, Massague J . Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003; 3(11):807-21. DOI: 10.1038/nrc1208. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View